Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 12/20 | 0.57 |
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901117 | 0.84 | FGFR3 (0.63) | FGFR3KDRMAPK1PIK3CAMAPK8 | |
| SCHEMBL15884313 | 0.84 | FGFR3 (0.56) | FGFR3KDRMAPK1PIK3CAMAPK8 | |
| SCHEMBL15884215 | 0.84 | FGFR3 (0.56) | FGFR3KDRMAPK1PIK3CAMAPK8 | |
| SCHEMBL17035979 | 0.81 | MAPK1 (0.55) | FGFR3KDRMAPK1PIK3CAMAPK8 | |
| SCHEMBL17035977 | 0.81 | MAPK1 (0.60) | FGFR3KDRMAPK1PIK3CAMAPK8 | |
| SCHEMBL17035976 | 0.77 | FGFR3 (0.61) | FGFR3KDRMAPK1PIK3CAMAPK8 | |
| SCHEMBL16257036 | 0.77 | FGFR3 (0.72) | FGFR3KDRMAPK1FGFR1FGFR2 | |
| SCHEMBL20571790 | 0.76 | FGFR3 (0.49) | FGFR3KDRMAPK1PIK3CAMAPK8 | |
| SCHEMBL24289863 | 0.75 | FGFR3 (0.67) | FGFR3KDRMAPK1FGFR1FGFR2 | |
| SCHEMBL29833181 | 0.75 | FGFR3 (0.67) | FGFR3KDRMAPK1FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861584-B1 | Pyridopyrazine and naphthyridine derivatives for the treatment of cancer | ASTEX THERAPEUTICS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-20160213677-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-20160213677-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239883-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | FGFR3 2473/4885KDR 2707/4885MAPK1 2950/4885 |
| US-20160213677-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | FGFR3 2473/4885KDR 2707/4885MAPK1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.